Celgene

Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Flag link:
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Celgene
Acceleron
Reblozyl
anemia
beta thalassemia
Flag link:
Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
Yahoo/Zacks.com
Celgene
earnings
Flag link:
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation
Yahoo/Businesswire
Bristol-Myers Squibb
Celgene
M&A
Flag link:
A change of the guard for the world’s biggest cancer companies
A change of the guard for the world’s biggest cancer companies
EP Vantage
cancer
Bristol-Myers Squibb
Celgene
M&A
Roche
AstraZeneca
Flag link:
As Celgene becomes BMS, its I&I lead lands CEO job at Takeda spinoff
As Celgene becomes BMS, its I&I lead lands CEO job at Takeda spinoff
Fierce Biotech
Celgene
Bristol-Myers Squibb
M&A
Terrie Curran
Phathom
Flag link:
3 Biotechs With the Biggest Cash Stockpiles
3 Biotechs With the Biggest Cash Stockpiles
Motley Fool
biotech
cash
Gilead Sciences
Amgen
Celgene
Flag link:
Roche and Celgene set for battle in acute myelogenous leukaemia
Roche and Celgene set for battle in acute myelogenous leukaemia
EP Vantage
Celgene
Roche
AML
acute myeloid leukemia
CC-486
Venclexta
Flag link:
Celgene's AML drug clears late-stage test
Celgene's AML drug clears late-stage test
Endpoints
Celgene
AML
CC-486
acute myeloid leukemia
Flag link:
Celgene's phase 3 AML test chalks up a win
Celgene's phase 3 AML test chalks up a win
Fierce Biotech
Celgene
acute myeloid leukemia
CC-486
clinical trials
Flag link:
[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug
[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug
Motley Fool
FTC
Amgen
Celgene
Bristol-Myers Squibb
M&A
Otezla
Flag link:
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
Endpoints
Roche
Tecentriq
FDA
Europe
Celgene
Abraxane
triple negative breast cancer
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
Yes, Amgen overpaid for Otezla—but that doesn't make it a mistake: analysts
Yes, Amgen overpaid for Otezla—but that doesn't make it a mistake: analysts
Fierce Pharma
Amgen
Otezla
Enbrel
drug reps
M&A
Celgene
Flag link:
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
Flag link:
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Xconomy
Celgene
cell therapies
drug development
Immatics
cancer
Flag link:
Six burning Otezla questions
Six burning Otezla questions
EP Vantage
Celgene
Otezla
Amgen
drug pricing
FTC
Tyk2
Bristol-Myers Squibb
Flag link:
Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps
Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps
Endpoints
Bristol-Myers Squibb
Celgene
Presage Biosciences
Phase 0 testing
drug development
Flag link:

Pages